Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Neutral

MedX Announces Final Closing of Non-brokered Private Placement

MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

By The Northwire Desk — AI Analysis May 15, 2026 · 19:40 MDX · 0.05 Medx Health Corp.
Executive Summary
  • MedX Health Corp. announced the final closing of its Series IV Convertible Loan Notes private placement on May 15, 2026.
  • Total notes issued amount to $2,800,000 face value.
  • Breakdown includes $2,400,000 from surrender/conversion of existing Series I notes and $400,000 in new cash subscriptions ($300k initial + $100k subsequent).
  • Proceeds designated for SIAscopy® technology development on the DermSecure® platform, occupational health market expansion, and general corporate purposes.
  • Terms include 6% annual interest payable quarterly, maturing December 31, 2028.
  • Conversion terms allow holders to convert notes into units at $0.10 per unit (1 share + ½ warrant).
  • Warrants are exercisable for one common share at $0.125 until maturity.
Material Impact
  • The financing was announced in February 2026 and extended in March, making the final closing an expected event rather than a surprise catalyst.
  • The actual new cash raised is only $400,000, which is modest for a company developing technology and expanding into new markets.
  • The majority of the funding ($2.4M) is a debt swap (Series I to Series IV), primarily extending maturity and refinancing existing obligations rather than providing significant growth capital.
  • Conversion price of $0.10 is double the current trading price of $0.05, indicating potential dilution risk if holders convert, though currently out-of-the-money.
  • The event prevents immediate default on Series I notes but does not materially alter the company's long-term valuation or operational trajectory in isolation.
MDX · Price
Company Overview
  • Flagship Project: SIAscopy® technology on the DermSecure® telemedicine platform.
  • Technology: AI-driven skin analysis using an image database of ~85,000 clinically reviewed images (blood, melanin, collagen components).
  • Divisions: Includes Photobiomodulation division with products LumaVet (veterinary) and Oralase (dental).
  • Operations: Serves Contract Research Organizations (CROs) and beauty brands; released from exclusive P&G licensing to pursue direct opportunities.
Read the original news release →

More from Medx Health Corp.

Jun 25, 2026 · 23:52

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

Other Mar 16, 2026 · 07:00

MedX Announces Application for Extension of Non-Brokered Private Placement

Financings Feb 27, 2026 · 11:44

MedX Health closes $2.7-million private placement

Financings Feb 27, 2026 · 07:00

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings Feb 02, 2026 · 21:05

MedX Health arranges $5-million note financing

Financings Feb 02, 2026 · 17:01

MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings